As of today (2023-04-02), Incyte's share price is $72.27.
Incyte's Owner Earnings per Share (TTM) ended in Dec. 2022 was $2.56. It's Price-to-Owner-Earnings for today is 28.23.
The historical rank and industry rank for Incyte's Price-to-Owner-Earnings or its related term are showing as below:
INCY'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 27.48 Med: 47.89 Max: 3774.33
Current: 28.29
During the past 13 years, the highest Price-to-Owner-Earnings of Incyte was 3774.33. The lowest was 27.48. And the median was 47.89.
INCY's Price-to-Owner-Earnings is ranked better than 57.14% of 168
companies
in the Biotechnology industry
Industry Median: 37.24
vs INCY: 28.29
As of today (2023-04-02), Incyte's share price is $72.27.
Incyte's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was $1.52. Therefore, Incyte's PE Ratio for today is 47.55.
As of today (2023-04-02), Incyte's share price is $72.27.
Incyte's EPS without NRI for the trailing twelve months (TTM) ended in was $1.52. Therefore, Incyte's PE Ratio without NRI for today is 47.55.
During the past 13 years, Incyte's highestPE Ratio without NRI was 11323.00. The lowest was 15.32. And the median was 54.25.
Incyte Price-to-Owner-Earnings Historical Data
The historical data trend for Incyte's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Incyte Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Price-to-Owner-Earnings
229.57
38.72
-
37.37
31.42
Incyte Quarterly Data
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Price-to-Owner-Earnings
37.37
41.09
45.19
32.41
31.42
Competitive Comparison
For the Biotechnology subindustry, Incyte's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incyte Price-to-Owner-Earnings Distribution
For the Biotechnology industry and Healthcare sector, Incyte's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Incyte's Price-to-Owner-Earnings falls in comparison to its industry or sector. The grey bar indicates the Price-to-Owner-Earnings's extreme value range as defined by GuruFocus.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Incyte's Price-to-Owner-Earnings for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Incyte's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Create New Portfolio
Portfolio Contest
Personalize
Premium Gurus 
1.23(1.73%) Volume: 1,960,924 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
INCY has been successfully added to your 
